Multistate Modeling of COVID-19 Patients Using a Large Multicentric Prospective Cohort of Critically Ill Patients.
acute respiratory distress disease
intensive unit care
survival
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
02 Feb 2021
02 Feb 2021
Historique:
received:
12
12
2020
revised:
12
01
2021
accepted:
26
01
2021
entrez:
5
2
2021
pubmed:
6
2
2021
medline:
6
2
2021
Statut:
epublish
Résumé
The mortality of COVID-19 patients in the intensive care unit (ICU) is influenced by their state at admission. We aimed to model COVID-19 acute respiratory distress syndrome state transitions from ICU admission to day 60 outcome and to evaluate possible prognostic factors. We analyzed a prospective French database that includes critically ill COVID-19 patients. A six-state multistate model was built and 17 transitions were analyzed either using a non-parametric approach or a Cox proportional hazard model. Corticosteroids and IL-antagonists (tocilizumab and anakinra) effects were evaluated using G-computation. We included 382 patients in the analysis: 243 patients were admitted to the ICU with non-invasive ventilation, 116 with invasive mechanical ventilation, and 23 with extracorporeal membrane oxygenation. The predicted 60-day mortality was 25.9% (95% CI: 21.8%-30.0%), 44.7% (95% CI: 48.8%-50.6%), and 59.2% (95% CI: 49.4%-69.0%) for a patient admitted in these three states, respectively. Corticosteroids decreased the risk of being invasively ventilated (hazard ratio (HR) 0.59, 95% CI: 0.39-0.90) and IL-antagonists increased the probability of being successfully extubated (HR 1.8, 95% CI: 1.02-3.17). Antiviral drugs did not impact any transition. In conclusion, we observed that the day-60 outcome in COVID-19 patients is highly dependent on the first ventilation state upon ICU admission. Moreover, we illustrated that corticosteroid and IL-antagonists may influence the intubation duration.
Identifiants
pubmed: 33540733
pii: jcm10030544
doi: 10.3390/jcm10030544
pmc: PMC7867229
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : P400PM_183865
Organisme : Bangerter-Rhyner Foundation
ID : xxx
Références
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
Thromb Res. 2020 Jul;191:148-150
pubmed: 32381264
JAMA. 2020 Oct 6;324(13):1330-1341
pubmed: 32876694
Intensive Care Med. 2020 Jun;46(6):1089-1098
pubmed: 32367170
Stat Med. 2007 May 20;26(11):2389-430
pubmed: 17031868
Lancet. 2020 Jun 6;395(10239):1763-1770
pubmed: 32442528
Ann Rheum Dis. 2020 Sep;79(9):1143-1151
pubmed: 32719045
Nat Med. 2020 Oct;26(10):1636-1643
pubmed: 32839624
Clin Microbiol Infect. 2021 Jan;27(1):105-111
pubmed: 32971254
Crit Care. 2020 Aug 27;24(1):524
pubmed: 32854738
Med Decis Making. 2017 May;37(4):340-352
pubmed: 27281337
Clin Infect Dis. 2020 Nov 5;71(8):1937-1942
pubmed: 32301997
JAMA. 2020 Oct 6;324(13):1307-1316
pubmed: 32876695
Arthritis Rheumatol. 2020 Aug 2;:
pubmed: 32741139
Lancet Rheumatol. 2020 Jul;2(7):e437-e445
pubmed: 32835247
JAMA Intern Med. 2020 Jul 15;:
pubmed: 32667668
BMC Med Res Methodol. 2020 Aug 11;20(1):206
pubmed: 32781984
Clin Infect Dis. 2020 Sep 23;:
pubmed: 32964913
BMJ. 2020 May 22;369:m1966
pubmed: 32444366
Stat Methods Med Res. 2002 Apr;11(2):91-115
pubmed: 12040698
Clin Infect Dis. 2020 Aug 12;:
pubmed: 32785710
Crit Care Med. 2011 Aug;39(8):1886-95
pubmed: 21516036
J Allergy Clin Immunol. 2020 Jul;146(1):128-136.e4
pubmed: 32425269
Clin Microbiol Infect. 2020 Nov 5;:
pubmed: 33161150
Clin Infect Dis. 2020 Nov 19;71(16):2061-2065
pubmed: 32337591
PLoS One. 2020 Jul 10;15(7):e0235653
pubmed: 32649661
BMC Public Health. 2015 Oct 23;15:1082
pubmed: 26498223
N Engl J Med. 2020 Jul 17;:
pubmed: 32678530
Int J Infect Dis. 2020 Dec;101:290-297
pubmed: 33035673